510(k) · Cleared
ClearedIG_Plex Celiac DGP Panel
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Sqi Diagnostics Systems, Inc. · MVM Autoantibodies, Endomysial (Tissue Transglutaminase)
Cleared on Nov 6, 2014 as substantially equivalent to K052143 (Inova Diagnostics, Inc., 2005) and 4 other predicates after a 232-day review. Its family tree reaches back 2 generations to 2005.
- Decided
- Nov 6, 2014
- Review
- 232 days
- Class
- Class II
- Product code
- MVM
- Recalls
- None
- Predicates
- 5
Its longest line of descent runs back 2 generations to K042644 (2005). 6 ancestors in all, the oldest K011566 (2001). No later device cites it as a predicate yet.
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K042644 | Aeskulisa TTG a and Aeskulisa TTG G | Aesku, Inc. | 2005 | 1 |
| −1 | K102490 | Igx Plex Celiac Qualitative Assay | Sqi Diagnostics Systems | 2011 | — |
| 0 (this device) | K140691 | IG_Plex Celiac DGP Panel | Sqi Diagnostics Systems, Inc. | 2014 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2001 | 2 | 0 |
| 2005 | 2 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in MVM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new MVM device
- #1 K200230 Aptiva Celiac Disease IgG Reagentscore 2.2 · 2 generations · no Class I recall
- #2 Held for the reportin the report
What was it cleared against? (5)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K052143 | Quanta Lite Gliadin Iga IISummary page 5…mentation for Clinical Multiplex Test Systems Substantial Equivalence: Inova Diagnostics, Inc. assays: Quanta Lite™ Gliadin IgA II (k052143) Quanta Lite™ Gliadin IgG II (k052142) Quanta Lite™ h-tTG IgA… | 2005 |
| * | K052142 | Quanta Lite Gliadin Igg IISummary page 5…Inova Diagnostics, Inc. assays: Quanta Lite™ Gliadin IgA II (k052143) Quanta Lite™ Gliadin IgG II (k052142) Quanta Lite™ h-tTG IgA ELISA (k011566) Quanta Lite™ h-tTG Ig… | 2005 |
| * | K011566 | Quanta Lite H-TTG (Human Tissue Transglutaminase) Iga ElisaSummary page 5…ta Lite™ Gliadin IgA II (k052143) Quanta Lite™ Gliadin IgG II (k052142) Quanta Lite™ h-tTG IgA ELISA (k011566) Quanta Lite™ h-tTG IgG ELISA (k011570) SQI Diagnostics SQiDw… | 2001 |
| * | K011570 | Quanta Lite H-TTG (Human Tissue Transglutaminase) Igg ElisaSummary page 5…a Lite™ Gliadin IgG II (k052142) Quanta Lite™ h-tTG IgA ELISA (k011566) Quanta Lite™ h-tTG IgG ELISA (k011570) SQI Diagnostics SQiDworks™ Diagnostics Platform (k102490) SQI Diagnostics Inc., 36 Meteor… | 2001 |
| * | K102490 | Igx Plex Celiac Qualitative AssaySummary page 5…ISA (k011566) Quanta Lite™ h-tTG IgG ELISA (k011570) SQI Diagnostics SQiDworks™ Diagnostics Platform (k102490) SQI Diagnostics Inc., 36 Meteor Dr. Toronto ON M9W 1A4 tel. (416) 674-9500, fax (416) 674-9300… | 2011 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 9 years and passes through 3 companies; a new generation was cleared every 6.0 years on median.
- 1 of the 6 ancestors has a recall of any class.
- 3 other devices also cite its predicate K052143.
How does its category compare?
All MVM devicesMVM Autoantibodies, Endomysial (Tissue Transglutaminase): FDA decisions, review times, recalls and adverse event reports over 20 years. 2014, this device’s year, is highlighted.
FDA decisions per year · MVM
2in 2021
2026 to Oct 25, outlined.
Median 510(k) review, days · MVM
275in 2011
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · MVM
No recall names MVM since 2007.
Adverse event reports per year · MVM
1in 2024
MAUDE reports naming product code MVM, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 2 | — | 0 | 0 |
| 2008 | 3 | 98 | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 2 | — | 0 | 0 |
| 2011 | 3 | 275 | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 2 | — | 0 | 0 |
| 2014 | 1 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 1 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 2 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 2 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 1 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The Ig_plex Celiac DGP Panel is an in vitro diagnostic test for the semi-quantitative detection of the IgA and IgG immunoglobulin classes of antibodies to deamidated gliadin peptide (DGP) and tissue transglutaminase (tTG) in human serum. The test is intended for use in clinical laboratories as an aid in the diagnosis of celiac disease in conjunction with other laboratory and clinical findings, and requires the sqid-X system.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K140691 · printed Nov 4, 2026
Cite this page
510(k) Report. “K140691: IG_Plex Celiac DGP Panel.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K140691
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026